Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...

Today, as part of a national initiative funded by The John A. Hartford Foundation (JAHF), the national, independent nonprofit FAIR Health launched a new shared decision-making tool for Alzheimer's ...

WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise Researchers at Washington University School of Medicine in St. Louis have ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Today, as part of a national initiative funded by The John A. Hartford Foundation (JAHF), the national, independent nonprofit ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...

H. Lundbeck A/S (Lundbeck) today announced that amlenetug has received Fast Track designation from the United States (US) Food and Drug Administration (FDA).

KAMPALA - Dr Matthias Magoola says the US Patent and Trademark Office (USPTO) has granted a patent for his invention of the first treatment of cancer using a novel composition of a guided Ribonucleic ...

Agenus Inc. , a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that ...